Stay updated on Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page.

Latest updates to the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedAdded a Locations section listing California, Georgia, and Nebraska as study sites.SummaryDifference0.4%

- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page no longer shows the government funding lapse notice that described NIH operations and potential processing delays.SummaryDifference0.3%

- Check67 days agoChange DetectedNo significant changes detected between the two screenshots; the study details page content and layout remain the same.SummaryDifference0.4%

- Check95 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. Overall, the page now communicates current operating status and a newer version rather than the old one.SummaryDifference2%

- Check102 days agoChange DetectedMinor capitalization updates for disease names and a version bump from v3.0.2 to v3.1.0. No substantive changes to core content or availability.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Pralatrexate in T-Cell Lymphomas Clinical Trial page.